15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Bright Minds Biosciences Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $145.00 to $220.00, a moderate spread. The average target of $164.25 sits 144% above the current $67.30. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.84 next quarter toward $-8.16 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Bright Minds Biosciences Inc.
As of Sep, 5 of 5 firms rate DRUG a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DRUG EPS & revenue forecast
EPS · NEXT QUARTER
$-1.84
Range $-2.72 – $-1.21 · 4 analysts · +89% YoY
Next period, 4 analysts expect Bright Minds Biosciences Inc to earn $-1.84 a share (range $-2.72 – $-1.21), versus $-0.97 a year earlier. Full-year consensus is $-3.65, growing to $-8.16 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $30.2M next year.
Top analysts covering Bright Minds Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DRUG.
#1
Yasmeen Rahimi
Piper Sandler · Rank #188
Buy
$220.00+226.9% to target
Overall win rate
33%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #230
Buy
$145.00+115.5% to target
Overall win rate
36%
+ Follow
#3
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #233
Buy
No targeton DRUG
Overall win rate
36%
+ Follow
#4
Thomas Shrader
BTIG
Buy
$147.00+118.4% to target
Coverage
—
+ Follow
#5
Andrew Tsai
Jefferies
Buy
$145.00+115.5% to target
Coverage
—
+ Follow
DRUG stock forecast FAQ
What is DRUG's average 12-month price target?+
The 4 analysts with a live target average $164.25 for Bright Minds Biosciences Inc over the next 12 months, ranging from a $220.00 high to a $145.00 low.
Is DRUG stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for DRUG?+
The Street-high target is $220.00 (Piper Sandler), and the Street-low is $145.00 (HC Wainwright & Co.). The average of all 4 active targets is $164.25.
How many Wall Street analysts cover DRUG?+
5 analysts have an active rating on Bright Minds Biosciences Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering DRUG?+
Among analysts who currently cover DRUG, Yasmeen Rahimi of Piper Sandler has the strongest overall Quantellect track record (Rank #188). Their current call is Buy with a $220.00 target.
What is Bright Minds Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-1.84 per share (range $-2.72 – $-1.21) across 4 analysts. Full-year EPS is projected at $-3.65, rising to $-8.16 the following year.
How much revenue is Bright Minds Biosciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $30.2M next year.
Have analysts been upgrading or downgrading DRUG lately?+
As of Sep, 5 of 5 firms rate DRUG a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DRUG calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
